Daiwa Securities Group
CNTA

Daiwa Securities Group’s Centessa Pharmaceuticals CNTA Stock Holding History

Daiwa Securities Group’s Portfolio CNTA Stock Details CNTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-294
Closed -$7K – 1240
2025
Q4 		$7K Hold
294
– – ﹤0.01% 1207
2025
Q3 		$7K Hold
294
– – ﹤0.01% 1179
2025
Q2 		$4K Hold
294
– – ﹤0.01% 1165
2025
Q1 		$4K Hold
294
– – ﹤0.01% 1142
2024
Q4 		$5K Buy
294
+83
+39% +$1.38K ﹤0.01% 1162
2024
Q3 		$3K Hold
211
– – ﹤0.01% 1196
2024
Q2 		$2K Hold
211
– – ﹤0.01% 1245
2024
Q1 		$2K Hold
211
– – ﹤0.01% 1263
2023
Q4 		$2K Hold
211
– – ﹤0.01% 1267
2023
Q3 		$1K Hold
211
– – ﹤0.01% 1243
2023
Q2 		$1K Hold
211
– – ﹤0.01% 1265
2023
Q1 		$1K Hold
211
– – ﹤0.01% 1246
2022
Q4 		$1K Buy
+211
New +$782 ﹤0.01% 1264

Other funds holding CNTA

MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
IVLAV
Index Venture Life Associates VI St. Helier, Jersey $396M AUM 176.22% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Daiwa Securities Group's CNTA Position: Q1 2026 in Review

Daiwa Securities Group sold out of Centessa Pharmaceuticals (CNTA) in Q1 2026, closing a stake of 294 shares — an estimated $7K sold.

Daiwa Securities Group first reported a position in CNTA in Q4 2022 and held it in 13 quarters. The position peaked at $7K in Q4 2025. 161 funds tracked by Wall St. Rank hold CNTA as of Q1 2026.

  • Daiwa Securities Group reported no remaining Centessa Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Daiwa Securities Group sold 294 Centessa Pharmaceuticals shares in Q1 2026, an estimated $7K.
  • Daiwa Securities Group first reported a position in Centessa Pharmaceuticals in Q4 2022 and held it in 13 quarters.
  • Daiwa Securities Group's Centessa Pharmaceuticals position peaked at $7K in Q4 2025.
  • 161 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q1 2026.

Based on Daiwa Securities Group's 13F filing for Q1 2026, filed 13 May 2026.